☆ 4.6 Letter

DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype

BRITISH JOURNAL OF HAEMATOLOGY (2017)

Get Full Text
Add to Collection

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 177, Issue 5, Pages 818-822

Publisher

WILEY
DOI: 10.1111/bjh.14115

Keywords

myelodysplastic syndrome; mesenchymal stromal cell; mesenchymal stem cell; azacitidine; demethylating agents

Categories

Hematology

Funding

  1. Associazione Italiana contro le leucemie, linfomi e mieloma (AIL), sezione di Ancona-ONLUS

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.